Please use this identifier to cite or link to this item:
http://doi.org/10.25358/openscience-8327
Authors: | Linz, Valerie Catherine Schwanbeck, Carina Krajnak, Slavomir Anic, Katharina Jäkel, Jörg Schwab, Roxana Schmidt, Marcus Schmidberger, Heinz Hasenburg, Annette Battista, Marco Johannes |
Title: | Comparison of cisplatin and mitomycin C/5-FU as radiosensitisers in the treatment of locally advanced vulvar cancer : results of a retrospective, observational, single-institutional cohort study |
Online publication date: | 30-Jan-2023 |
Year of first publication: | 2022 |
Language: | english |
Abstract: | Purpose We retrospectively investigated the widely used radiosensitisers cisplatin and mitomycin C/5-fluorouracil (5-FU) in patients with locally advanced vulvar cancer for outcome and toxicity. Methods We screened the archive for patients treated with chemoradiation for vulvar cancer diagnosed between 01/2010 and 08/2021 at our institution. The impact of both radiosensitisers on prognosis was compared using Kaplan–Meier method and Cox-regression analysis. Results One hundred and forty-three patients with vulvar cancer were screened. Twenty-nine patients received chemoradiation (mitomycin C/5-FU n = 14; cisplatin n = 12; others n = 3) as a primary, neoadjuvant or adjuvant treatment. Median follow-up was 15.5 months. Patients in the cisplatin group were older (mean age 54.4 vs. 70.7; p = 0.004). However, the mitomycin C/5-FU group had more advanced tumour stages. The 2-year recurrence-free survival (RFS) was comparable (44.5% vs. 33.3%; p = 0.932). The 2-year overall survival (OS) showed a numerical but not statistically significant difference in favour of the mitomycin C/5-FU group (59.7% vs. 31.7%; p = 0.37). 64.3% (9 out of 14) patients, who received mitomycin C/5-FU achieved clinical complete response (cCR) compared to 41.7% (5 out of 12) who received cisplatin (p = 0.505). Radiodermatitis was the most common adverse event in both groups (81%) and more severe in the mitomycin C/5-FU cohort. Myelotoxicity was frequently observed in both groups. Eighteen patients received an additional radiation boost with 10.0 (9–16) Gy and showed a significantly prolonged RFS (p = 0.027) and OS (p = 0.003). Conclusion Mitomycin C/5-FU may be considered in the treatment of young and healthy patients with locally advanced vulvar cancer. |
DDC: | 610 Medizin 610 Medical sciences |
Institution: | Johannes Gutenberg-Universität Mainz |
Department: | FB 04 Medizin |
Place: | Mainz |
ROR: | https://ror.org/023b0x485 |
DOI: | http://doi.org/10.25358/openscience-8327 |
Version: | Published version |
Publication type: | Zeitschriftenaufsatz |
License: | CC BY |
Information on rights of use: | https://creativecommons.org/licenses/by/4.0/ |
Journal: | Journal of cancer research and clinical oncology Version of Record (VoR) |
Publisher: | Springer |
Publisher place: | Berlin u.a. |
Issue date: | 2022 |
ISSN: | 1432-1335 |
Publisher DOI: | 10.1007/s00432-022-04006-0 |
Appears in collections: | DFG-491381577-H |
Files in This Item:
File | Description | Size | Format | ||
---|---|---|---|---|---|
comparison_of_cisplatin_and_m-20221117145309607.pdf | 818.75 kB | Adobe PDF | View/Open |